Europe Pen Needle Market is predicted to reach USD 1.88 billion at a CAGR of 8.61% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global Europe Pen Needle Market”.

The Europe pen needle market is projected to register a CAGR of 8.61% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the Europe Pen Needle market— Novo Nordisk A/S, Terumo Corporation, Nipro Europe Group Companies, hanghai Beipu Medical Co., LTD., Promisemed Medical Devices Inc., TaeChang Industrial Co., Ltd., Vitrex Medical A/S, Embecta Corp., Ypsomed Holding AG, MTD Medical Technology and Devices and others.

Europe Pen Needle Market Highlights

The Europe Pen Needle market is accounted to register a CAGR of 8.61% during the forecast period and is estimated to reach USD 1.88 billion by 2032.

The growth of the Europe Pen Needle market is attributed to the increasing prevalence of diabetes, obesity, and other chronic diseases rising awareness of self-administration, and patient preference for pen devices. For instance, according to the World Health Organisation (WHO) in 2023, there are approximately 60 million diabetics in the European Region, accounting for 10.3% of men and 9.6% of women aged 25 and up. Diabetes is becoming more common in people of all ages across Europe, owing primarily to increases in overweight and obesity, an unhealthy diet, and physical inactivity.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Europe Pen Needle Market

Segment Analysis

Based on product, the Europe pen needles market is bifurcated into standard pen needle and safety pen needle.

Based on needle length, the Europe pen needle market has been segmented into 4mm, 5mm, 6mm, 8mm, 10mm, and 12.7mm.

Based on application, the Europe pen needle market has been segmented into insulin therapy, GLP-1 therapy, growth hormone therapy, osteoporosis, and others.

Based on the distribution channel, the Europe pen needle market has been segmented into direct sales and distributors.

Based on end user, the Europe pen needle market has been segmented into hospitals & clinics, homecare settings, and others.

Regional Analysis

Europe spearheaded the pen needles market in 2022 and is likely to continue to command during the assessment period. This can be attributed to the rising prevalence of infectious diseases, new product approvals, and the presence of developed healthcare infrastructure in most European countries.

Key Findings of the Study

• The Europe Pen Needle market is expected to reach USD 1.88 billion by 2032 at a CAGR of 8.61% during the forecast period.


• The Rest of the Europe region held the second largest market share of the Europe market, due to increasing prevalence of diabetes, obesity, and other chronic diseases rising awareness of self-administration, and patient preference for pen devices.


• Novo Nordisk A/S, Terumo Corporation, Nipro Europe Group Companies, hanghai Beipu Medical Co., LTD., Promisemed Medical Devices Inc., TaeChang Industrial Co., Ltd., Vitrex Medical A/S, Embecta Corp., Ypsomed Holding AG, MTD Medical Technology and Devices and others and others are the key players in the market.